和元生物收盘下跌3.39%，最新市净率2.39，总市值38.81亿元

Group 1 - The core viewpoint of the news is that He Yuan Bio is experiencing a decline in stock price and financial performance, indicating potential challenges in the biotechnology sector focused on gene therapy [1] - As of the first quarter of 2025, He Yuan Bio reported a revenue of 52.84 million yuan, a year-on-year decrease of 11.29%, and a net loss of approximately 59.48 million yuan, reflecting a year-on-year decline of 41.04% [1] - The company's gross profit margin is reported at -36.44%, indicating significant financial strain [1] Group 2 - He Yuan Bio's current market capitalization is approximately 3.881 billion yuan, with a price-to-earnings (PE) ratio of -11.45 [2] - The company has a price-to-book (PB) ratio of 2.39, which is higher than the industry average of 2.64 [2] - The biotechnology industry average PE ratio is 38.04, while the median is 42.05, suggesting that He Yuan Bio is underperforming compared to its peers [2]